Inc Research Holdings, Inc. (INCR): D. Jamie Macdonald , Chief Executive Officer of Inc Research Holdings, Inc. sold 53,970 shares on Sep 27, 2016. The Insider selling transaction was reported by the company on Sep 28, 2016 to the Securities and Exchange Commission. The shares were sold at $44.31 per share for a total value of $2,391,061.50 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 28, 2016, Robert W Breckon (director) sold 12,197 shares at $44.31 per share price.On Sep 20, 2016, David F Burgstahler (director 10% owner) purchased 1,000 shares at $43.19 per share price.Also, On Sep 16, 2016, Christopher L Gaenzle (CAO, GC & Sec) sold 4,734 shares at $43.14 per share price.On Aug 18, 2016, Alistair Macdonald (Chief Operating Officer) sold 8,828 shares at $43.80 per share price.
INC Research Holdings Inc: On Tuesday, Sep 27, 2016 heightened volatility was witnessed in INC Research Holdings Inc which led to swings in the share price. The shares opened for trading at $44.24 and hit $44.75 on the upside , eventually ending the session at $44.725, with a gain of 0.75% or 0.335 points. The heightened volatility saw the trading volume jump to 3,25,203 shares. The 52-week high of the share price is $57.11 and the company has a market cap of $2,447 M . The 52-week low of the share price is at $34.19.
INC Research Holdings Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company’s segment Clinical Development Services offers a variety of clinical development services including global studies clinical monitoring investigator recruitment patient recruitment data management and study reports. The Company’s segment Phase I Services focuses on clinical development services for Phase I trials that include scientific exploratory medicine first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The Company’s segment Global Consulting provides consulting services regarding clinical trial regulatory affairs regulatory consulting services quality assurance audits and pharmacovigilance consulting non-clinical consulting and medical writing consulting.